Galera Therapeutics, Inc. is a clinical stage biotechnology company, which engages in developing and commercializing a pipeline of novel, proprietary therapeutics for cancer. The company is headquartered in Malvern, Pennsylvania and currently employs 3 full-time employees. The company went IPO on 2019-11-07. The firm is focused on advancing a pan-NOS inhibitor through clinical development for patients with the hardest-to-treat forms of advanced breast cancer.
Galera Therapeutics Inc'in kazanç kalite puanı B+/55.227386'dir. Puan, karlılık, büyüme, nakit üretimi ve sermaye tahsisi ile kaldıraç olmak üzere dört boyuta dayanır.
Galera Therapeutics Inc kazançlarını ne zaman rapor eder?
Galera Therapeutics Inc'in bir sonraki kazanç raporu 2026-02-11'te bekleniyor